uniQure: AMT-130 phase I/II data show sustained functional benefit at 36—48 months

uniQure reported AMT-130 high-dose data showing continued slowing of Huntington’s disease progression at 36 and 48 months.Key Highlights:Original SEC Filing: uniQure N.V. [ QURE ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important informati…